Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of In8bio, Inc. (INAB) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of In8bio, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1740279.
Total stock buying since 2021: $10,571,304.
Total stock sales since 2021: $0.
Total stock option exercises since 2021: $84,073.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 0 | $0 | 304,688 | $56,061 |
| 2023 | 27,300 | $28,395 | 0 | $0 | 0 | $0 |
| 2022 | 4,962,587 | $9,542,909 | 0 | $0 | 26,204 | $28,012 |
| 2021 | 100,000 | $1,000,000 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-04 | 0 | $0 | 0 | $0 | 304,688 | $56,061 |
| 2023-09 | 2,500 | $2,375 | 0 | $0 | 0 | $0 |
| 2023-08 | 24,800 | $26,020 | 0 | $0 | 0 | $0 |
| 2022-12 | 150,002 | $371,854 | 0 | $0 | 0 | $0 |
| 2022-09 | 50,000 | $101,050 | 0 | $0 | 0 | $0 |
| 2022-08 | 4,762,585 | $9,070,005 | 0 | $0 | 0 | $0 |
| 2022-05 | 0 | $0 | 0 | $0 | 26,204 | $28,012 |
| 2021-08 | 100,000 | $1,000,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-04-30 | Rochlin Kate (Chief Operating Officer) | Option Ex | 12,295 | .18 | 2,262 |
| 2025-04-30 | Mccall Patrick (CHIEF FINANCIAL OFFICER) | Option Ex | 15,000 | .18 | 2,760 |
| 2025-04-30 | Roemer Alan S. | Option Ex | 113,459 | .18 | 20,876 |
| 2025-04-30 | Brandt Peter C. | Option Ex | 163,934 | .18 | 30,163 |
| 2023-09-13 | Graff Jeremy R. (Director) | Buy | 2,500 | .95 | 2,375 |
| 2023-08-25 | Mccall Patrick (Chief Financial Officer) | Buy | 1,000 | 1.03 | 1,030 |
| 2023-08-24 | Ho William Tai-wei (President and CEO) | Buy | 23,800 | 1.05 | 24,990 |
| 2022-12-12 | Bios Advisors Gp, Llc | Buy | 75,001 | 2.48 | 185,927 |
| 2022-12-12 | Cavu Advisors, Llc | Buy | 75,001 | 2.48 | 185,927 |
| 2022-09-28 | Bios Advisors Gp, Llc | Buy | 25,000 | 2.02 | 50,525 |
| 2022-09-28 | Cavu Advisors, Llc | Buy | 25,000 | 2.02 | 50,525 |
| 2022-08-29 | Cavu Advisors, Llc | Buy | 80,000 | 2.02 | 161,600 |
| 2022-08-26 | Cavu Advisors, Llc | Buy | 22,428 | 2.01 | 45,080 |
| 2022-08-17 | Bios Advisors Gp, Llc | Buy | 50,000 | 1.93 | 96,500 |
| 2022-08-17 | Cavu Advisors, Llc | Buy | 50,000 | 1.93 | 96,500 |
| 2022-08-16 | Rochlin Kate (Chief Operating Officer) | Buy | 5,263 | 1.90 | 9,999 |
| 2022-08-16 | Goswami Trishna (Chief Medical Officer) | Buy | 2,631 | 1.90 | 4,998 |
| 2022-08-16 | Mccall Patrick (Chief Financial Officer) | Buy | 5,263 | 1.90 | 9,999 |
| 2022-08-16 | Greenwood Luba (Director) | Buy | 526 | 1.90 | 999 |
| 2022-08-16 | Transcend Partners Opportunity Fund Llc (10% Owner) | Buy | 789,473 | 1.90 | 1,499,998 |
| 2022-08-16 | Ho William Tai-wei (President, CEO and CFO) | Buy | 26,315 | 1.90 | 49,998 |
| 2022-08-16 | Lamb Lawrence (EVP and CSO) | Buy | 526 | 1.90 | 999 |
| 2022-08-16 | Bios Advisors Gp, Llc | Buy | 1,773,684 | 1.90 | 3,369,999 |
| 2022-08-16 | Cavu Advisors, Llc | Buy | 1,773,684 | 1.90 | 3,369,999 |
| 2022-08-16 | Roemer Alan S. (Director) | Buy | 26,315 | 1.90 | 49,998 |
| 2022-08-16 | Brandt Peter C. (Director) | Buy | 105,263 | 1.90 | 199,999 |
| 2022-05-05 | Lamb Lawrence (EVP and CSO) | Option Ex | 26,204 | 1.07 | 28,012 |
| 2021-08-03 | Transcend Partners Opportunity Fund Llc (10% Owner) | Buy | 100,000 | 10.00 | 1,000,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of INAB listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of In8bio, Inc. (symbol INAB, CIK number 1740279) see the Securities and Exchange Commission (SEC) website.